Coronavirus: European Commission continues expanding future vaccines portfolio with new talks
August 20, 2020
The European Commission has concluded exploratory talks with CureVac to purchase a potential vaccine against COVID-19 on 20 August. This is following the positive steps with Sanofi-GSK on 31 July and Johnson & Johnson on 13 August and the signature of an Advance Purchase Agreement with AstraZeneca on 14 August.
The envisaged contract with CureVac would provide for the possibility for all EU Member States to purchase the vaccine, as well as to donate to lower and middle income countries or re-direct to European countries. It is anticipated that the Commission will have a contractual framework in place for the initial purchase of 225 million doses on behalf of all EU Member States, to be supplied once a vaccine has proven to be safe and effective against COVID-19. The Commission pursues intensive discussions with other vaccine manufacturers.
On 6 July, the European Investment Bank and CureVac signed a €75 million loan agreement for the development and large-scale production of vaccines, including CureVac’s vaccine candidate against COVID-19.